

Tecan appoints Dr. Klaus Lun to the Management Board

Männedorf, Switzerland, May 23, 2013 – The Tecan Group (SIX Swiss Exchange: TECN) announced today that Dr. Klaus Lun has been appointed Head of Corporate Development and a member of the Management Board. He will take up his new post at Tecan on June 4, 2013.

Tecan CEO David Martyr commented: “Our strategic goal is to evolve Tecan in the medium term from a highly specialized instrument supplier to a provider of complete solutions. We’re also working to grow the company via non-organic means through very carefully selected acquisitions and collaborations. Klaus Lun has the ideal background for this position, with several years of experience in Corporate Development as well as responsibility for an operating division in our sector. Whilst at Leica Microsystems, I already worked successfully with Klaus Lun on a number of takeovers and have come to know him as an extremely focused and well-organized manager with a strategic way of thinking. We are delighted that Klaus Lun is going to be joining our management team, strengthening us in this strategically vital area.”

Klaus Lun has extensive experience in a variety of management positions in the life science industry. Since 2011, he worked at Molecular Devices Inc., a company belonging to the Danaher Group. As Vice President Drug Discovery and Bioresearch, Klaus Lun was responsible for running the Drug Discovery and Bioresearch business. Most recently, he became Vice President Global Product Marketing with responsibility for strategy development, positioning and marketing for the entire product portfolio.

Klaus Lun was Director Business Development from 2007 to 2011 at Leica Microsystems, also part of the Danaher Group, where he was responsible for corporate mergers, takeovers and licensing. In this capacity, he managed several takeovers by Leica Microsystems and successfully integrated the newly acquired companies into its existing business operations. Klaus Lun was also closely involved in a number of transactions entered into by the parent company Danaher.

From 2002 to 2007, Klaus Lun held a variety of positions at Amaxa GmbH, which is now part of the Lonza Group, most recently as a Senior Project Manager with responsibility, among other things, for the development and rollout onto the market of a variety of clinical products.

Klaus Lun studied biology at the University of Tübingen and gained his doctorate in neurobiology at the University of Heidelberg. He also has an MBA from the University of Mannheim. Klaus Lun is 40 years old and an Italian citizen.



2

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2012, Tecan generated sales of CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group

Martin Braendle

Head of Corporate Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com